Antibody Drug Conjugates Contract Manufacturing Market Size Worth $18.4 Billion By 2028: Grand View Research, Inc.

News provided by

Nov 09, 2021, 05:35 ET

SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- The global antibody drug conjugates contract manufacturing market size is anticipated to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.3% from 2021 to 2028. The factors driving market expansion is complex nature of Antibody Drug Conjugates (ADCs), increasing demand for manufacturing capacity as well as increasing number of research on antibody therapies.

Key Insights & Findings:

By condition, the myeloma segment dominated the market and accounted for the largest revenue share of 49.4% in 2020. This is largely due to the fact that antibody-drug conjugates are a novel form of immunotherapy presently being researched and evaluated in the treatment of myeloma
Based on the linker, the cleavable linker segment accounted for a maximum share of 56.5% in 2020. Extensive use of cleavable linker technology in ADC and a greater number of cleavable linker-based authorised products are the factor responsible for the growth
Asia Pacific dominated the market in 2020 due to the robust improvements in research and development activities, emerging markets, and competition in the pharmaceutical CMO sector
In 2018, nearly 202 ADCs have entered the clinical trials and there were about 23 novel ADCs in the last 12 months increasing at a rate of 30.0%

Read 110 page market research report, "Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer), By Linker (Cleavable Linker, Non-cleavable Linker), By Region, And Segment Forecasts, 2021 - 2028", by Grand View Research

Around 70.0% of ADC projects are outsourced to contract development and manufacturing organisations. As ADCs are complex molecules, they require clean room biologic and high containment cytotoxic facilities for safe handling. Hence, there are real opportunities for companies that can provide specialised, innovative chemistries that require skilled workers.

ADCs are currently a niche market, with few CMOs offering all of the drug's components, resulting in a complex supply chain. Besides, with seven commercially authorised ADC on the market and roughly 90 projects in clinical trials, it is essential to reduce the complicated supply chain in order to increase production efficiency. For the success of the trial, a transparent and integrated supply chain is essential.

The coronavirus pandemic has assessed a typically optimistic and deliberate approach to monoclonal antibody development and disrupting supply chains not only for those antibodies deemed most promising a year ago, but also for others antibody drug conjugate that have been thrust into the spotlight as potential COVID-19 treatments.The COVID-19 pandemic has generated a strong and quick reaction from scientists working in government, and industries to create medicines and vaccines. As a result of the increasing demand for effective COVID-19 treatment medicines, global production of vaccines, antibody drug conjugates, and other pharmaceuticals is projected to expand.

Grand View Research has segmented the global antibody drug conjugates contract manufacturing market on the basis of condition, linker, and region:

Antibody Drug Conjugates Contract Manufacturing Condition Outlook (Revenue, USD Million, 2016 - 2028)

Myeloma
Lymphoma
Breast Cancer
Others (Urothelial Cancer)

Antibody Drug Conjugates Contract Manufacturing Linker Outlook (Revenue, USD Million, 2016 - 2028)

Cleavable Linker
Non-cleavable Linker

Antibody Drug Conjugates Contract Manufacturing Regional Outlook (Revenue, USD Million, 2016 - 2028)

North America

U.S.
Canada

Europe

Germany
U.K.
France
Italy
Spain

Asia Pacific

China
Japan
India
South Korea
Australia

Latin America

Mexico
Brazil
Argentina

South Africa
Saudi Arabia
UAE

List of Key Players of the Antibody Drug Conjugates Contract Manufacturing Market

Cambrex
ReciPharm
ThermoFisher
Pantheon
Corden Pharma
Samsung Biologics
Lonza
Catalent
Siegfried
Piramal Pharma Solutions
Boehringer Ingelheim

Check out more studies related to contract manufacturing, conducted by Grand View Research:

Healthcare Contract Manufacturing Market – The global healthcare contract manufacturing market size was valued at USD 177.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.7% from 2021 to 2028. An increase in offshoring to emerging countries and the changing regulatory landscape are the prominent trends currently present in the market.
Pharmaceutical Contract Manufacturing & Research Services Market – The global pharmaceutical contract manufacturing and research services market size was valued at USD 174.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.75% from 2021 to 2028. Cost-saving and time-saving benefits associated with the implementation of outsourcing are responsible for driving the market.
Biopharmaceuticals Contract Manufacturing Market – The global biopharmaceuticals contract manufacturing market size was valued at USD 15.8 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.7% during the forecast period. The success of the biopharmaceutical market can be majorly attributed to the contract manufacturers.

Browse through Grand View Research's coverage of the Global Medical Devices Industry

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

SOURCE Grand View Research, Inc.